Retatrutide Results Suggest a Change in the Order of Things
Eli Lilly’s phase‑3 trial of retatrutide, a triple‑agonist peptide, showed patients with severe obesity lost an average of 30% of body weight over 80 weeks, a result comparable to bariatric surgery. The study also reported significant improvements in cardiometabolic markers such as blood pressure and lipid profiles. These topline results suggest that pharmacologic therapy can now achieve surgical‑level weight loss, prompting a reassessment of the traditional step‑wise obesity treatment model. The data are still pending peer‑review and FDA submission, but the headline figures have already sparked industry buzz.
Is Preclinical Obesity a Problematic Concept?
A new study in *Obesity* examined records of 261,408 patients receiving obesity treatment and found that up to one‑third could be classified as “preclinical obesity” under the Lancet Commission’s proposed framework. Critics argue the label could reclassify patients already seeking...
ECO2026: Lilly Gets Serious About Long-Term Obesity Care
At ECO2026 in Istanbul, Eli Lilly unveiled data from two landmark trials that reposition obesity as a chronic condition requiring sustained therapy. The SURMOUNT‑MAINTAIN study in The Lancet showed participants who continued full‑dose tirzepatide for 60 weeks largely preserved weight loss and...
Five Themes Likely to Emerge at ECO2026 in Istanbul
The 33rd European Congress on Obesity (ECO2026) in Istanbul is pivoting from a sole focus on body weight to a broader view of chronic disease management. Five dominant themes will shape the agenda: health‑outcome‑centric treatment, next‑generation therapeutics, obesity as a...
Is Novo Nordisk Turning the Page on CagriSema?
Novo Nordisk says its launch timeline for the dual‑agonist CagriSema remains unchanged despite scrapping a single‑chamber delivery device. The Phase 3 trial showed a 23% average weight loss over 84 weeks, impressive but still below Lilly’s tirzepatide at 25.5%. Meanwhile, Novo...
What Everyone Knows About Obesity, Nutrition, and Health
Two recent papers challenge the prevailing narrative on obesity and ultra‑processed foods. In a systematic review, nutrition researcher David Ludwig argues that most of the evidence linking ultra‑processed foods to obesity is observational, with scant experimental proof of causality. A...
Will Wegovy Tablets Spark a “Turnaround” At Novo Nordisk?
Novo Nordisk’s newly launched Wegovy oral tablet is delivering a rapid market surge, with over two million U.S. prescriptions and first‑quarter sales of about $350 million, outpacing expectations. Weekly new prescriptions reached roughly 200,000 by mid‑April, marking the fastest uptake for...
The Imperative for Equity in Obesity Care Is Alive and Well
At the ASMBS Annual Meeting, leaders highlighted that breakthroughs in metabolic surgery and anti‑obesity medications are undermined by stark inequities in access. Only a small fraction of eligible patients receive surgery, while high out‑of‑pocket costs keep new drugs out of...
ASMBS: Moving Into a New World of Obesity Care
The 2026 ASMBS meeting in San Antonio signaled a shift in obesity treatment from a sole focus on bariatric surgery to a broader, metabolic‑health‑centric model. Surge in GLP‑1 pharmacotherapy is reshaping patient expectations and clinical pathways, positioning drugs as partners...
Study of Food Noise Aims to Account for Lived Experience
Researchers are finally naming the intrusive, constant thoughts about food that patients call “food noise.” Two recent papers in Nutrition & Diabetes argue that these patient‑reported experiences deserve rigorous scientific study, while a TikTok content analysis shows the phenomenon is...
Yes, BeanTok Really Is a Thing – Who Knew?
BeanTok has exploded on TikTok, with more than half‑million videos promoting beans as a daily staple. Influencers urge users to eat two cups of beans each day—roughly four times the typical serving—to tap into trends around protein, fiber, and cost‑effective...
Zepbound Soars and Lilly Advises Patience on Foundayo
Eli Lilly reported a blockbuster first‑quarter, with revenue jumping 56% to $19.8 billion driven by soaring sales of its obesity drugs Zepbound and Mounjaro. Zepbound alone generated over $4 billion, up about 80% year‑over‑year, while Mounjaro nearly doubled to close to $9 billion. The...
Obesity Leaves a Lasting Mark on Your DNA
A new EMBO Reports study shows obesity creates lasting DNA methylation changes that survive weight loss, establishing an epigenetic memory in fat and immune cells. The research reveals that immune cells maintain a pro‑inflammatory state for months or years after...
Growing Signs That MAHA May Be Losing Momentum
The Movement for Authentic Health Advocacy (MAHA) surged in 2024, promising radical health‑policy reforms and attracting anti‑establishment voters. Recent reports show the Trump administration curbing Robert F. Kennedy Jr.'s influence, while New York Times surveys reveal growing voter disillusion as promised changes stall. Anti‑vaccine rhetoric...
Obesity Treatment: Still Judging After All These Years
A new study in Scientific Reports surveyed roughly 1,200 adults in the United States, United Kingdom and Belgium to examine how people judge individuals who lose weight with GLP‑1 obesity medicines versus lifestyle changes alone. Participants perceived medication‑assisted weight loss...